{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:45:19Z","timestamp":1789073119196,"version":"build-2803163510"},"reference-count":79,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2010,10,20]],"date-time":"2010-10-20T00:00:00Z","timestamp":1287532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Despite the eradication of smallpox several decades ago, variola and monkeypox viruses still have the potential to become significant threats to public health. The current licensed live vaccinia virus-based smallpox vaccine is extremely effective as a prophylactic vaccine to prevent orthopoxvirus infections, but because of safety issues, it is no longer given as a routine vaccine to the general population. In the event of serious human orthopoxvirus infections, it is important to have treatments available for individual patients as well as their close contacts. The smallpox vaccine and vaccinia immune globulin (VIG) were used in the past as therapeutics for patients exposed to smallpox. VIG was also used in patients who were at high risk of developing complications from smallpox vaccination. Thus post-exposure vaccination and VIG treatments may again become important therapeutic modalities. This paper summarizes some of the historic use of the smallpox vaccine and immunoglobulins in the post-exposure setting in humans and reviews in detail the newer animal studies that address the use of therapeutic vaccines and immunoglobulins in orthopoxvirus infections as well as the development of new therapeutic monoclonal antibodies.<\/jats:p>","DOI":"10.3390\/v2102381","type":"journal-article","created":{"date-parts":[[2010,10,21]],"date-time":"2010-10-21T03:00:15Z","timestamp":1287630015000},"page":"2381-2403","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections"],"prefix":"10.3390","volume":"2","author":[{"given":"Yuhong","family":"Xiao","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart N.","family":"Isaacs","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, USA"},{"name":"Infectious Diseases Section, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2010,10,20]]},"reference":[{"key":"ref_1","unstructured":"Fenner, F., Henderson, D.A., Arita, I., Jezek, Z., and Ladnyi, I.D. (1988). Smallpox and Its Eradication, World Health Organization. [1st ed.]. Preface, ix\u2013xii; Chapter 27."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1369-5274(98)80121-5","article-title":"The threat of bioterrorism returns the fear of smallpox","volume":"1","author":"Atlas","year":"1998","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1126\/science.283.5406.1279","article-title":"The looming threat of bioterrorism","volume":"283","author":"Henderson","year":"1999","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/nm917","article-title":"Duration of antiviral immunity after smallpox vaccination","volume":"9","author":"Hammarlund","year":"2003","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.4049\/jimmunol.171.10.4969","article-title":"Cutting edge: Long-term B cell memory in humans after smallpox vaccination","volume":"171","author":"Crotty","year":"2003","journal-title":"J. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.immuni.2008.02.020","article-title":"Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines","volume":"28","author":"Miller","year":"2008","journal-title":"Immunity"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1086\/375825","article-title":"Smallpox vaccination: A review, part II. Adverse events","volume":"37","author":"Fulginiti","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0891-5520(05)70332-9","article-title":"Postexposure prophylaxis","volume":"10","author":"Lutwick","year":"1996","journal-title":"Infect. Dis. Clin. North Am."},{"key":"ref_9","unstructured":"Dixon, C.W. (1962). Smallpox, Churchill. Chapter 14."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/rmv.361","article-title":"Studies in smallpox and vaccination. 1913","volume":"12","author":"Hanna","year":"2002","journal-title":"Rev. Med. Virol."},{"key":"ref_11","unstructured":"Rao, A.R. (1972). Smallpox, Korhari Book Depot. Chapter 17."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/oxfordjournals.aje.a121326","article-title":"A study of intrafamilial transmission of smallpox","volume":"94","author":"Heiner","year":"1971","journal-title":"Am. J. Epidemiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/oxfordjournals.aje.a121380","article-title":"Epidemiology of smallpox in West Pakistan. I. Acquired immunity and the distribution of disease","volume":"95","author":"Mack","year":"1972","journal-title":"Am. J. Epidemiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1086\/374054","article-title":"Can postexposure vaccination against smallpox succeed?","volume":"36","author":"Mortimer","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1099\/vir.0.82068-0","article-title":"Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus Ankara","volume":"87","author":"Staib","year":"2006","journal-title":"J. Gen. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nature04295","article-title":"Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection","volume":"439","author":"Stittelaar","year":"2006","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1086\/595565","article-title":"Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox","volume":"199","author":"Paran","year":"2009","journal-title":"J. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/14760584.8.1.13","article-title":"IMVAMUNE: Modified vaccinia Ankara strain as an attenuated smallpox vaccine","volume":"8","author":"Kennedy","year":"2009","journal-title":"Expert Rev. Vaccines"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"10889","DOI":"10.1073\/pnas.0804985105","article-title":"Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus","volume":"105","author":"Earl","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1172\/JCI33940","article-title":"Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection","volume":"118","author":"Samuelsson","year":"2008","journal-title":"J. Clin. Invest."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lauterbach, H., Kassub, R., Patzold, J., Korner, J., Bruckel, M., Verschoor, A., Chaplin, P., Suter, M., and Hochrein, H. (2010). Immune requirements of post-exposure immunization with modified vaccinia Ankara of lethally infected mice. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0009659"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"12921","DOI":"10.1073\/pnas.0505180102","article-title":"Interferon function is not required for recovery from a secondary poxvirus infection","volume":"102","author":"Panchanathan","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1128\/JVI.00115-06","article-title":"Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function","volume":"80","author":"Panchanathan","year":"2006","journal-title":"J. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/icb.2009.110","article-title":"Antiviral protection following immunization correlates with humoral but not cell-mediated immunity","volume":"88","author":"Panchanathan","year":"2010","journal-title":"Immun. Cell Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ijid.2005.12.001","article-title":"Vaccinia immune globulin: Current policies, preparedness, and product safety and efficacy","volume":"10","author":"Wittek","year":"2006","journal-title":"Int. J. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1086\/422998","article-title":"Safety and pharmacokinetic evaluation of intravenous vaccinia immune globulin in healthy volunteers","volume":"39","author":"Hopkins","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.ajog.2004.07.014","article-title":"Pregnancy discovered after smallpox vaccination: Is vaccinia immune globulin appropriate?","volume":"191","author":"Napolitano","year":"2004","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.virol.2004.05.004","article-title":"Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin","volume":"325","author":"Bell","year":"2004","journal-title":"Virology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/nm1457","article-title":"Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination","volume":"12","author":"Putz","year":"2006","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1099\/vir.0.008474-0","article-title":"Smallpox vaccines induce antibodies to the immunomodulatory, secreted vaccinia virus complement control protein","volume":"90","author":"Adamo","year":"2009","journal-title":"J. Gen. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1073\/pnas.0408782102","article-title":"Profiling the humoral immune response to infection by using proteome microarrays: High-throughput vaccine and diagnostic antigen discovery","volume":"102","author":"Davies","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.virol.2005.08.008","article-title":"Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin","volume":"343","author":"Garcia","year":"2005","journal-title":"Virology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1542\/peds.26.2.176","article-title":"Studies on smallpox and complications of smallpox vaccination","volume":"26","author":"Kempe","year":"1960","journal-title":"Pediatrics"},{"key":"ref_34","first-page":"328","article-title":"Passive immunity to vaccinia in newborns. I. Placental transmission of antibodies","volume":"24","author":"Kempe","year":"1952","journal-title":"Yale J. Biol. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1086\/423005","article-title":"Henry Kempe and the birth of vaccinia immune globulin","volume":"39","author":"Bray","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_36","first-page":"128","article-title":"Progressive vaccinia in immunologically deficient individuals","volume":"4","author":"Fulginiti","year":"1968","journal-title":"Birth Defects"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1203\/00006450-198011000-00002","article-title":"Acceptance of the Howland award","volume":"14","author":"Kempe","year":"1980","journal-title":"Pediat. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.4049\/jimmunol.172.3.1763","article-title":"Selective killing of vaccinia virus by LL-37: Implications for eczema vaccinatum","volume":"172","author":"Howell","year":"2004","journal-title":"J. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1084\/jem.20082835","article-title":"Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum","volume":"206","author":"Kawakami","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.4049\/jimmunol.0903144","article-title":"Skin inflammation arising from cutaneous regulatory T cell deficiency leads to impaired viral immune responses","volume":"185","author":"Freyschmidt","year":"2010","journal-title":"J. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1542\/peds.18.2.177","article-title":"Hyperimmune vaccinal gamma globulin: Source, evaluation, and use in prophylaxis and therapy","volume":"18","author":"Kempe","year":"1956","journal-title":"Pediatrics"},{"key":"ref_42","unstructured":"CDC (2007). Household transmission of vaccinia virus from contact with a military smallpox vaccinee\u2014Illinois and Indiana, 2007. MMWR Morb. Mortal. Wkly. Rep., 56, 478\u2013481."},{"key":"ref_43","first-page":"609","article-title":"Vaccinia gangrenosa treated with hyperimmune vaccinal gamma globulin","volume":"16","author":"Barbero","year":"1955","journal-title":"Pediatrics"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1086\/374244","article-title":"Progressive vaccinia","volume":"36","author":"Bray","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/archderm.1983.01650290044015","article-title":"Progressive vaccinia associated with combined variable immunodeficiency","volume":"119","author":"Keane","year":"1983","journal-title":"Arch. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0264-410X(96)00163-6","article-title":"A recombinant vaccinia-rabies virus in the immunocompromised host: Oral innocuity, progressive parenteral infection, and therapeutics","volume":"15","author":"Hanlon","year":"1997","journal-title":"Vaccine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/oxfordjournals.aje.a121057","article-title":"Prophylaxis of smallpox with methisazone","volume":"90","author":"Bauer","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1128\/AAC.49.7.2634-2641.2005","article-title":"Biological activity of an intravenous preparation of human vaccinia immune globulin in mouse models of vaccinia virus infection","volume":"49","author":"Shearer","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"9458","DOI":"10.1073\/pnas.1233578100","article-title":"Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses","volume":"100","author":"Belyakov","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.4049\/jimmunol.172.10.6265","article-title":"Cellular and humoral immunity against vaccinia virus infection of mice","volume":"172","author":"Xu","year":"2004","journal-title":"J. Immunol."},{"key":"ref_51","first-page":"41","article-title":"The use of vaccinia hyperimmune gamma-globulin in the prophylaxis of smallpox","volume":"25","author":"Kempe","year":"1961","journal-title":"Bull. World Health Organ."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0140-6736(62)91935-9","article-title":"Antivaccinial gamma-globulin in the control of smallpox","volume":"1","author":"Hobday","year":"1962","journal-title":"Lancet"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0140-6736(58)92023-3","article-title":"Smallpox in Tottenham; 1957","volume":"1","author":"Hogben","year":"1958","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(58)90351-9","article-title":"Anti-vaccinial gamma-globulin in smallpox prophylaxis","volume":"2","author":"Peirce","year":"1958","journal-title":"Lancet"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0140-6736(59)90480-5","article-title":"Antivaccinial gamma-globulin; a further report on smallpox prophylaxis","volume":"2","author":"Semple","year":"1959","journal-title":"Lancet"},{"key":"ref_56","first-page":"325","article-title":"The use of hyperimmune antivaccinia gamma-globulin for the prevention and treatment of smallpox","volume":"27","author":"Marennikova","year":"1962","journal-title":"Bull. World Health Organ."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1099\/vir.0.80660-0","article-title":"An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model","volume":"86","author":"Law","year":"2005","journal-title":"J. Gen. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.vaccine.2009.01.038","article-title":"Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response","volume":"27","author":"Lustig","year":"2009","journal-title":"Vaccine"},{"key":"ref_59","unstructured":"CDC (2009). Progressive vaccinia in a military smallpox vaccinee\u2014United States, 2009. MMWR Morb. Mortal. Wkly. Rep., 58, 532\u2013536."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1099\/0022-1317-83-12-2915","article-title":"The formation and function of extracellular enveloped vaccinia virus","volume":"83","author":"Smith","year":"2002","journal-title":"J. Gen. Virol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0065-3527(06)66002-8","article-title":"In a nutshell: Structure and assembly of the vaccinia virion","volume":"66","author":"Condit","year":"2006","journal-title":"Adv. Virus Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.virol.2005.09.037","article-title":"Poxvirus entry and membrane fusion","volume":"344","author":"Moss","year":"2006","journal-title":"Virology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1128\/jvi.56.2.482-488.1985","article-title":"Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus","volume":"56","author":"Rodriguez","year":"1985","journal-title":"J. Virol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.virol.2008.08.009","article-title":"Vaccinia virus entry\/fusion complex subunit A28 is a target of neutralizing and protective antibodies","volume":"380","author":"Nelson","year":"2008","journal-title":"Virology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"8750","DOI":"10.1128\/JVI.73.10.8750-8761.1999","article-title":"Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells","volume":"73","author":"Hsiao","year":"1999","journal-title":"J. Virol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"11724","DOI":"10.1128\/JVI.79.18.11724-11733.2005","article-title":"Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice","volume":"79","author":"Davies","year":"2005","journal-title":"J. Virol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1006\/viro.1995.1378","article-title":"A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies","volume":"211","author":"Wolffe","year":"1995","journal-title":"Virology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1006\/viro.1996.0337","article-title":"Neutralizing epitope on penetration protein of vaccinia virus","volume":"220","author":"Ichihashi","year":"1996","journal-title":"Virology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1006\/viro.1998.9516","article-title":"Neutralizing and protective antibodies directed against vaccinia virus envelope antigens","volume":"254","author":"Galmiche","year":"1999","journal-title":"Virology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1099\/0022-1317-83-5-1059","article-title":"Administration to mice of a monoclonal antibody that neutralizes the intracellular mature virus form of vaccinia virus limits virus replication efficiently under prophylactic and therapeutic conditions","volume":"83","author":"Ramirez","year":"2002","journal-title":"J. Gen. Virol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1128\/JVI.79.21.13454-13462.2005","article-title":"Combinations of Polyclonal or Monoclonal Antibodies to Proteins of the Outer Membranes of the Two Infectious Forms of Vaccinia Virus Protect Mice against a Lethal Respiratory Challenge","volume":"79","author":"Lustig","year":"2005","journal-title":"J. Virol."},{"key":"ref_72","unstructured":"Xiao, Y., and Isaacs, S.N. (2005). University of Pennsylvania, Philadelphia, PA, Unpublished work."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1073\/pnas.0510598103","article-title":"Chimpanzee\/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus","volume":"103","author":"Chen","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"8989","DOI":"10.1128\/JVI.00906-07","article-title":"Characterization of chimpanzee\/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model","volume":"81","author":"Chen","year":"2007","journal-title":"J. Virol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.virol.2004.07.024","article-title":"Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement","volume":"328","author":"Lustig","year":"2004","journal-title":"Virology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1128\/JVI.01797-08","article-title":"Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement","volume":"83","author":"Benhnia","year":"2009","journal-title":"J. Virol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"12355","DOI":"10.1128\/JVI.01593-09","article-title":"Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5","volume":"83","author":"Benhnia","year":"2009","journal-title":"J. Virol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1146\/annurev.immunol.21.120601.141049","article-title":"Poxviruses and immune evasion","volume":"21","author":"Seet","year":"2003","journal-title":"Annu. Rev. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1084\/jem.20071854","article-title":"The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination","volume":"205","author":"Xu","year":"2008","journal-title":"J. Exp. Med."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/2\/10\/2381\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:03:37Z","timestamp":1760220217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/2\/10\/2381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,20]]},"references-count":79,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2010,10]]}},"alternative-id":["v2102381"],"URL":"https:\/\/doi.org\/10.3390\/v2102381","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,20]]}}}